- $37.03m
- $31.02m
- $56.65m
Brief: Cvrx Reports Second Quarter 2023 Financial And Operating Results
Brief: CVRx Reports Second Quarter 2023 Financial and Operating Results
CVRx Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: CVRx Set To Join Russell 2000 & 3000 Indexes
U.S. RESEARCH ROUNDUP- Amazon.com, Boston Beer Company, Eli Lilly
CVRx Inc reports results for the quarter ended in March - Earnings Summary
CVRx Inc expected to post a loss of 56 cents a share - Earnings Preview
CVRx gains on positive heart failure therapy data in post-market trial
Brief: Totality Of Evidence From Beat-Hf Study Shows Cvrx’S Barostim Provides Long-Term Benefits For Patients With Heart Failure
Brief: Cvrx Reiterates Plans To Discuss The Preliminary Results From The Post-Market Phase Of The Beat-Hf Trial At Tht 2023 And Schedules A Conference Call
U.S. STOCKS ON THE MOVE-VerifyMe, Molson Coors, Sigma Lithium
CVRx tanks as heart failure therapy fails post-market trial
U.S. STOCKS ON THE MOVE-Chemomab, Home Depot, Teck Resources
CVRx slumps as heart failure therapy fails post-market trial
Brief: Cvrx Reports Preliminary Results Of The Beat-Hf Post-Market Randomized Clinical Trial
U.S. RESEARCH ROUNDUP-Allbirds, Lockheed Martin, Warby Parker
U.S. RESEARCH ROUNDUP-Driven Brands Holdings, McCormick & Company, Standex International
Brief: Cvrx Reports Q4 And Full Year 2022 Financial And Operating Results
CVRx Inc reports results for the quarter ended in December - Earnings Summary